Leadership transition Recent appointment of Mani Mohindru as President and CEO with prior interim leadership signals strategic continuity and potential renewed focus on commercial partnerships and financing opportunities to accelerate clinical programs and BD activities.

Clinical collaboration Lead asset onvansertib is being evaluated across combinations and indications (mCRC, mPDAC, TNBC, SCLC) with ACR/NCI-backed conferences and investigator-initiated trials, presenting multiple partnership and co-development opportunities with mid- to late-stage oncology programs.

Financial position Company operates with sub $1M revenue but has raised about $120M in funding, indicating runway for partnering discussions, licensing deals, and strategic collaborations to de-risk development milestones.

Preclinical momentum Upcoming and ongoing preclinical data presentations around onvansertib, including combinations with targeted agents like T-DXd, create openings for collaboration on translational research, combination study design, and joint IP opportunities.

Global exposure San Diego–based biotech with active investor activity, public Nasdaq listing, and participation in major events, providing multiple access points for potential strategic partners, co-development agreements, and market access discussions.